Security Snapshot

Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) Institutional Ownership

CUSIP: 45254E107

13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

87

Shares (Excl. Options)

31,752,244

Price

$6.58

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Class A common stock, par value $0.001 per share
Symbol
IMRX on Nasdaq
Shares outstanding
66,027,379
Price per share
$5.27
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
31,752,244
Total reported value
$208,911,171
% of total 13F portfolios
0%
Share change
+3,008,255
Value change
+$18,277,430
Number of holders
87
Price from insider filings
$5.27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • IMRX - Immuneering Corp - Class A common stock, par value $0.001 per share is tracked under CUSIP 45254E107.
  • 87 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 87 to 4 between Q4 2025 and Q1 2026.
  • Reported value moved from $208,911,171 to $492,192.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 87 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 45254E107?
CUSIP 45254E107 identifies IMRX - Immuneering Corp - Class A common stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 14% $71,526,603 8,787,052 FMR LLC 30 Sep 2025
Zeskind Benjamin J. 6.6% -48% $28,674,370 +$2,498,025 4,357,807 +9.5% BENJAMIN J. ZESKIND 31 Dec 2025
HBM Healthcare Investments (Cayman) Ltd. 5.7% $29,680,915 3,646,304 HBM Healthcare Investments (Cayman) Ltd. 26 Sep 2025
Empery Asset Management, LP 5% -43% $20,154,805 -$12,015,476 3,250,775 -37% Empery Asset Management, LP 31 Dec 2025

As of 31 Dec 2025, 87 institutional investors reported holding 31,752,244 shares of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX). This represents 48% of the company’s total 66,027,379 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 9,685,495 +10% 0% $63,730,557
Sanofi 4.1% 2,708,559 0% 5.7% $17,822,318
Empery Asset Management, LP 4.1% 2,674,950 0% 16% $17,601,171
VANGUARD GROUP INC 3.9% 2,568,293 +6.3% 0% $16,899,368
STATE STREET CORP 3.6% 2,402,238 +1290% 0% $15,806,726
PRICE T ROWE ASSOCIATES INC /MD/ 3% 1,993,958 +11% 0% $13,121,000
BlackRock, Inc. 2.2% 1,451,706 +113% 0% $9,552,225
MARSHALL WACE, LLP 1.1% 711,875 +162% 0% $4,684,136
Blue Owl Capital Holdings LP 1% 665,000 +21% 1.4% $4,375,700
GEODE CAPITAL MANAGEMENT, LLC 0.94% 618,074 +20% 0% $4,068,348
Occam Crest Management LP 0.75% 498,498 0% 2.4% $3,280,117
MORGAN STANLEY 0.74% 489,617 +66% 0% $3,221,679
GOLDMAN SACHS GROUP INC 0.48% 318,809 0% $2,097,763
BURKEHILL GLOBAL MANAGEMENT, LP 0.45% 300,000 0% 0.13% $1,974,000
SOUTHPORT MANAGEMENT, L.L.C. 0.42% 277,501 +1.8% 6.4% $1,825,957
Diametric Capital, LP 0.37% 246,857 -2.1% 0.44% $1,624,319
BARCLAYS PLC 0.35% 230,726 +943% 0% $1,518,177
DCF Advisers, LLC 0.33% 215,000 0.47% $1,414,700
BANK OF AMERICA CORP /DE/ 0.32% 214,341 +390% 0% $1,410,364
TWO SIGMA INVESTMENTS, LP 0.31% 207,155 +92% 0% $1,363,080
UBS Group AG 0.29% 190,333 +51% 0% $1,252,391
Qube Research & Technologies Ltd 0.25% 165,875 0% $1,091,458
RENAISSANCE TECHNOLOGIES LLC 0.23% 152,300 +335% 0% $1,002,134
683 Capital Management, LLC 0.23% 150,697 0.08% $991,586
Woodline Partners LP 0.23% 150,000 0% 0% $987,000

Institutional Holders of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 93,471 $492,192 +$178,643 $5.27 4
2025 Q4 31,752,244 $208,911,171 +$18,277,430 $6.58 87
2025 Q3 26,061,962 $182,434,908 +$152,080,293 $7.00 69
2025 Q2 3,829,641 $12,906,115 -$684,732 $3.37 39
2025 Q1 4,498,583 $6,835,562 +$160,625 $1.52 34
2024 Q4 4,238,711 $9,324,244 -$178,796 $2.20 41
2024 Q3 4,355,017 $10,869,922 -$7,529,696 $2.49 38
2024 Q2 9,594,278 $12,279,759 -$9,114,134 $1.28 57
2024 Q1 11,871,050 $34,309,079 -$12,746,356 $2.89 50
2023 Q4 16,130,676 $118,561,919 -$6,044,147 $7.35 52
2023 Q3 16,940,765 $130,107,793 -$5,076,687 $7.68 52
2023 Q2 17,269,962 $175,881,466 +$55,986,602 $10.14 49
2023 Q1 11,823,558 $114,882,649 +$3,734,772 $9.71 34
2022 Q4 11,722,865 $56,864,840 -$4,241,513 $4.85 32
2022 Q3 12,063,607 $172,475,348 -$5,229,083 $14.32 30
2022 Q2 12,148,741 $65,706,270 -$8,960,781 $5.41 33
2022 Q1 13,611,716 $88,116,760 -$3,464,272 $6.47 49
2021 Q4 12,489,185 $199,826,000 +$5,452,786 $16.17 36
2021 Q3 12,105,226 $316,421,451 +$316,421,451 $26.55 38

Sponsored